Teva Pharmaceutical Industries Limited (TEVA)
Teva Pharmaceutical Industries Statistics
Share Statistics
Teva Pharmaceutical Industries has 1.15B shares outstanding. The number of shares has increased by 1.17% in one year.
| Shares Outstanding | 1.15B |
| Shares Change (YoY) | 1.17% |
| Shares Change (QoQ) | 0.99% |
| Owned by Institutions (%) | 58.67% |
| Shares Floating | 1.15B |
| Failed to Deliver (FTD) Shares | 3.82K |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -15.21 and the forward PE ratio is 4.95. Teva Pharmaceutical Industries's PEG ratio is -0.08.
| PE Ratio | -15.21 |
| Forward PE | 4.95 |
| PS Ratio | 1.51 |
| Forward PS | 1.1 |
| PB Ratio | 4.63 |
| P/FCF Ratio | 33.28 |
| PEG Ratio | -0.08 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Teva Pharmaceutical Industries.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.98, with a Debt / Equity ratio of 3.36.
| Current Ratio | 0.98 |
| Quick Ratio | 0.75 |
| Debt / Equity | 3.36 |
| Debt / EBITDA | -59.67 |
| Debt / FCF | 24.14 |
| Interest Coverage | -0.3 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $488.14K |
| Profits Per Employee | $-48.36K |
| Employee Count | 33,892 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 2.82 |
Taxes
| Income Tax | 355M |
| Effective Tax Rate | -27.65% |
Stock Price Statistics
The stock price has increased by 10.82% in the last 52 weeks. The beta is 0.72, so Teva Pharmaceutical Industries's price volatility has been higher than the market average.
| Beta | 0.72 |
| 52-Week Price Change | 10.82% |
| 50-Day Moving Average | 15.35 |
| 200-Day Moving Average | 17.54 |
| Relative Strength Index (RSI) | 59.52 |
| Average Volume (20 Days) | 12.52M |
Income Statement
In the last 12 months, Teva Pharmaceutical Industries had revenue of 16.54B and earned -1.64B in profits. Earnings per share was -1.45.
| Revenue | 16.54B |
| Gross Profit | 8.06B |
| Operating Income | -303M |
| Net Income | -1.64B |
| EBITDA | -303M |
| EBIT | -282M |
| Earnings Per Share (EPS) | -1.45 |
Balance Sheet
The company has 3.3B in cash and 18.08B in debt, giving a net cash position of -14.78B.
| Cash & Cash Equivalents | 3.3B |
| Total Debt | 18.08B |
| Net Cash | -14.78B |
| Retained Earnings | -15.17B |
| Total Assets | 39.33B |
| Working Capital | -244M |
Cash Flow
In the last 12 months, operating cash flow was 1.25B and capital expenditures -498M, giving a free cash flow of 749M.
| Operating Cash Flow | 1.25B |
| Capital Expenditures | -498M |
| Free Cash Flow | 749M |
| FCF Per Share | 0.66 |
Margins
Gross margin is 48.74%, with operating and profit margins of -1.83% and -9.91%.
| Gross Margin | 48.74% |
| Operating Margin | -1.83% |
| Pretax Margin | -7.76% |
| Profit Margin | -9.91% |
| EBITDA Margin | -1.83% |
| EBIT Margin | -1.83% |
| FCF Margin | 4.53% |
Dividends & Yields
TEVA pays an annual dividend of $1.19, which amounts to a dividend yield of 5.8%.
| Dividend Per Share | $1.19 |
| Dividend Yield | 5.8% |
| Dividend Growth (YoY) | 0% |
| Payout Ratio | -82.07% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for TEVA is $24.5, which is 57.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $24.5 |
| Price Target Difference | 57.4% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Stock Splits
The last stock split was on Jul 1, 2004. It was a forward split with a ratio of 2:1.
| Last Split Date | Jul 1, 2004 |
| Split Type | forward |
| Split Ratio | 2:1 |
Scores
| Altman Z-Score | 0.69 |
| Piotroski F-Score | 4 |